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Mary EapenA study by Bertz et al. [1] in this issue of Biology of
Blood andMarrow Transplantation shows that the results
of unrelated donor hematopoietic stem cell transplant
for adults with acute myelogenous leukemia or myelo-
dysplastic syndrome are better with transplantation of
peripheral blood progenitor cells (PBPCs) compared
to bone marrow (BM). Overall mortality risks were
lower after transplantation of PBPC compared to
BM. With a median follow-up of 10 years, event-free
survival rate after PBPC transplants was 55% and
significantly higher compared to 28% after BM trans-
plants. This is in contrast to the findings of a random-
ized multicenter trial of unrelated donor PBPC vs BM
for hematologic malignancies in North America [2].
That trial randomized 273 patients to receive PBPC
and 278 patients to receive BM. With a median
follow-up of 3 years, event-free survival rates were not
significantly different after PBPC and BM transplants,
47% and 44%, respectively [2]. However, the incidence
of chronic graft-versus-host disease (cGVHD) was
more after transplantation of PBPC compared to BM
grafts (53% vs 40%; P 5 .02) and without significant
differences in non-relapse mortality rates between the
2 treatment groups [2]. Bertz et al. [1] also report
more cGVHD after PBPC compared to BM trans-
plants, but the observed difference was not statistically
significant (52% vs 33%; P 5 .11). The probability es-
timates reported by Bertz et al. [1] and Anasetti et al. [2]
are similar. Relatively few events in the small patient
population in the report by Bertz et al. [1] are the
most likely explanation for their inability to detect
statistically significant differences in cGVHD rates
between the 2 graft sources.
The reported higher event-free survival rate in the
PBPC group with a median follow-up of 10 years is
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unrelated donor hematopoietic stem cell transplanta-
tion [3,4]. In a recent report, Weisdorf et al. [5]
specifically explored for an effect of acute or cGVHD
on long-term disease-free survival in 4000 patients
with acute myelogenous leukemia or myelodysplastic
syndrome who received myeloablative or reduced in-
tensity transplantation conditioning regimens. Treat-
ment failure was significantly higher in patients with
cGVHD only (relative risk, 1.62; P 5 .0002) or those
with acute or cGVHD (relative risk, 1.85; P\ .0001)
after myeloablative transplantation [5]. Longer
follow-up of those patients enrolled in the randomized
clinical trial [2] is planned and subsequent analysesmay
or may not confirm the findings of Bertz et al. [1].
Needless to say, with approximately 80% of unrelated
donor adult transplantations favoring PBPC over BM
grafts, it will be important to more definitively define
the relative merit of one graft source compared to the
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